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INTRODUCTION 
Type 2 diabetes mellitus is an established risk factor for cardiovascular 
events and the development of congestive cardiac failure, through its 
association with hypertension and coronary artery disease.  The existence of 
myocardial dysfunction in diabetic subjects even in the absence of ischemic, 
valvular and hypertensive heart disease was proposed by Rubler et al. in 
1972 and subsequently abnormalities in both systolic and diastolic functions 
have been demonstrated. 
Diastolic dysfunction has been described as an early sign of diabetic heart 
muscle disease preceding the systolic damage.  Diastolic abnormalities in 
normotensive type 2 diabetic patients without coronary artery disease and 
clinical evidence of heart failure was demonstrated by Regan et al. using 
cardiac catheterization and subsequently by noninvasive techniques such as 
Doppler echocardiography. 
Diastolic dysfunction is independently associated with increased all-cause 
mortality as well as cardiovascular mortality in a population based sample 
of middle aged and elderly adults.  The impact of isolated diastolic 
dysfunction in diabetes concerns exercise tolerability.  It influences 
maximal treadmill performance and explains lower maximal performance 
observed in patients with type 2 diabetes. 
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Diabetic complications can be classified broadly as microvascular and 
macrovascular complications.  The influence of diabetic complications on 
diastolic dysfunction has been investigated in several studies.  
Abnormalities have been observed especially in population of diabetic 
patients with severe microvascular complications as evidenced by marked 
proteinuria and proliferative retinopathy. 
Studies (Takenakaet al.(1988), Hiramatsuet al.(1992),Annonuet al(2001))   
performed in diabetic patients free of coronary artery disease, have 
demonstrated that patients with mild to severe retinopathy exhibited LV 
diastolic dysfunction.  This relation with retinopathy, was however 
constantly not found. 
Sampson et al(1990) found a significantly higher proportion of abnormal 
diastolic dysfunction in the group of diabetes with proteinuria. Watschinger 
et al.(1993) and Guglielmi et al.(1995) demonstrated LV diastolic 
dysfunction, whereas controls without microalbuminuria showed no 
diastolic impairment.  
The pathogenesis of diastolic dysfunction in type 2 diabetic patients is not 
completely elucidated.  The relation of microvascular complications with 
diastolic dysfunction in type 2 diabetics suggests that diabetic 
microangiopathy is a background factor.  
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AIM OF THE STUDY 
 
Primary Objectives 
To assess the diastolic dysfunction in type 2 diabetic patients using Doppler 
echocardiography. 
 
Secondary Objectives 
To find out the correlation between diastolic dysfunction and microvascular  
complications (nephropathy and retinopathy). 
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REVIEW OF LITERATURE 
Diabetes mellitus has been a disease known to the society from time 
immemorial. Descriptions of patients presenting with folliculitis, weight 
loss, polyuria and urine that attracted ants have been found in writings from 
earliest civilizations of Asian and Indian origin
1
. Since then, descriptions 
and our understanding of this disorder have kept growing as evidenced from 
reports all across the globe. 
What started in 17
th
 century as tasting human urine to detect blood sugar 
levels has now grown into sophisticated laboratory diagnostic testing. And it 
does not stop here. With growing technology, our insight into the disease, its 
complications and the possible pathogenesis keeps growing. This 
development is essential, as supported by the growing pandemic of diabetes. 
It has been estimated that nearly 285 million people are affected by diabetes 
mellitus by the year 2010 and it shows no signs of regression in the near 
future. The estimates continue to increase with atleast 438 million people to 
be affected by the year 2030
2
. Diabetes mellitus being the most common 
cause of end stage renal disease (ESRD), non-traumatic lower limb 
amputations and blindness in the United States, is an indication of how 
much health burden the disorder can cause. It lays emphasis on treating the 
complications aggressively but more important would be to detect the 
complications at the earliest and prevent their progression. 
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UNDERSTANDING DIABETES MELLITUS: 
Diabetes mellitus is a group of metabolic disorders resulting in 
hyperglycemia with disturbances in carbohydrate, fat and protein 
metabolism. Hyperglycemia may result from a defect in insulin secretion, 
insulin action or both. Hyperglycemia when present for a long period of 
time leads to a host of metabolic abnormalities and also results in end organ 
damage. 
With previous classifications of diabetes being based upon the age of onset 
and requirement for insulin, presently the emphasis is on the underlying 
pathogenic process. Diabetes mellitus is classified broadly as Type 1 and 
Type 2 although other subtypes do exist. Type 1 diabetes mellitus results 
from complete or near total insulin deficiency whereas type 2 diabetes 
mellitus is a result of combination of insulin resistance, impaired insulin 
secretion and increased glucose production.  
The etiologic classification of diabetes as recommended by the WHO and 
ADA extends beyond type 1 and type 2 diabetes and is as follow
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Type 1 diabetes mellitus 
Type 2 diabetes mellitus 
Other specific types of diabetes: 
1. Genetic defects of beta cell function 
2. Genetic defects of insulin secretion 
3. Diseases of exocrine pancreas 
4. Endocrinopathies 
5. Drugs/chemical induced 
6. Infections 
Gestational diabetes 
 
Since our study is limited to the population of type 2 diabetes, further 
discussion is restricted to type 2 diabetes, its pathogenesis and 
complications. 
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TYPE 2 DIABETES MELLITUS 
EPIDEMIOLOGY AND RISK FACTORS: 
Type 2 diabetes is the most common form of diabetes. Previously termed as 
non-insulin dependent diabetes, type 2 diabetes occurs as a result of a 
combination of insulin resistance, impaired insulin secretion and increased 
glucose production. 
 Although the incidence of both type 1 and type 2 diabetes is increasing, 
type 2 diabetes has become a rapidly growing pandemic attributed to factors 
like increased prevalence of obesity and increased aging. Type 2 diabetes 
though present worldwide, the highest prevalence is in the Pacific islands 
and Middle East. Not only does the prevalence rate vary in different 
geographic regions, but the pattern of presentation also varies. Patients from 
Asian ethnicity have an intermediate prevalence pattern (7-9% of the total 
population) and phenotypically differ from the rest of the world by having a 
lower BMI, younger age at onset, presence of greater visceral adiposity and 
a decreased insulin secretory capacity. 
These patients may not require insulin at the time of diagnosis, but may 
require insulin later in the disease course for glycemic control. Type 2 
diabetes patients usually have a gradual onset of hyperglycemia and hence 
do not present with the classic symptoms of polyuria, polydipsia and 
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polyphagia. Although type 2 diabetes is undiagnosed in many due to lack of 
symptoms, the risk of developing complications remain the same. So there 
is a need to screen people at a higher risk of developing diabetes. 
Risk factors for developing type 2 diabetes include 
1. Family history of diabetes (i.e., parent or sibling with type 2 
diabetes)  
2. Obesity (BMI >25 kg/m2) 
3. Physical inactivity 
4. Race/ethnicity (e.g., African American, Latino, Native American, 
Asian American, Pacific Islander) 
5. Previously identified with IFG, IGT, or an HbA1C of 5.7–6.4% 
6. History of GDM or delivery of baby >4 kg (9 lb) 
7. Hypertension (blood pressure 140/90 mmHg)  
8. HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or a 
triglyceride level >250 mg/dL (2.82 mmol/L) 
9. Polycystic ovary syndrome or acanthosis  nigricans 
10. History of cardiovascular disease3 
PATHOGENESIS 
The two important pathogenic mechanisms implicated in type 2 diabetes are 
insulin resistance and decreased insulin secretion, which is due to genetic 
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factors, environmental factors and obesity either in single or in 
combination.Insulin resistance may result from mutations in the insulin 
receptor or polymorphisms of insulin signaling pathways. The genetic basis 
for type 2 diabetes is supported by the fact that the concordance of type 2 
diabetes among identical twins is more than 70%. Individuals with both 
parents having diabetes carry a risk of 40% of developing diabetes. 
Variation of transcriptor factor 7 gene has been associated with impaired 
glucose tolerance and diabetes mellitus. 
Data suggest that inflammation and diabetes are closely related. Adipose 
tissue besides being a principal storage site of energy, also acts as an 
endocrine organ. Obesity mediates insulin resistance by elaborating 
inflammatory cytokines (adipokines). Adipocyte cell size highly correlates 
with insulin resistance and the risk of developing type 2 diabetes
4
. Visceral 
obesity, which includes both mesenteric and omental fat deposits correlates 
better than overall obesity5. Proposed mechanisms include an unrestrained 
lipolysis with an increased delivery of free fatty acids (FFA) to the portal 
circulation. 
Another contributory pathogenic mechanism is the decrease in insulin 
secretion due to a beta cell dysfunction. During the early phase, beta cells 
increase insulin release in an attempt to compensate for insulin resistance. 
As the disease progresses, there is a progressive decline in beta cell 
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function. To start with, the insulin secretory defect is limited to the glucose 
stimulated insulin secretion. Eventually, there is decrease in overall insulin 
secretory capacity. There is also a reduction in the mass of the beta cells. 
Type 2 diabetes is also associated with amyloid deposition in the islet cells. 
Whether amyloid deposition is a cause or effect remains a controversy.  
Any given patient with type 2 diabetes, at the time of diagnosis, will have 
both insulin resistance and beta cell dysfunction in varying degrees. 
COMPLICATIONS 
 
Chronic 
complications of 
diabetes
Vascular
Microvascular 
(retinopathy, 
neuropathy, 
nephropathy)
Macrovascular
(Stroke, CAD, 
PAD)
Non vascular
Gastoparesis, 
skin disease, 
infections
11 
 
The complications of type 2 diabetes can be acute or chronic. Chronic 
complications are primarily responsible for morbidity and mortality of 
diabetes. Chronic complications may be vascular or nonvascular in nature. 
Vascular complications of diabetes can be classified into microvascular and 
macrovascular complications. 
Macrovascular complications include coronary artery disease, peripheral 
arterial disease and cerebrovascular accidents (stroke).Traditionally 
microvascular complications have been described under the headings of 
neuropathy, nephropathy and retinopathy. 
PATHOGENESIS OF MICROVASCULAR COMPLICATIONS: 
There is a need to understand the molecular and cellular mechanisms of 
microvascular complications in order to device strategies that will aim at 
treatment and prevention of these complications. Chronic hyperglycemia 
and associated metabolic abnormalities due to a insulin secretory defect or 
insulin resistance have profound influences on the cellular function, 
extracellular matrix and organ function. The important mechanisms that 
contribute to microvascular complications are 
a) Sympathetic nervous system: Overactivity of sympathetic nervous 
system contributes to the development of hypertension.
6
 During late 
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stages of diabetes, sympathetic denervation occur leading to altered 
vascular responses.
7
 
b) Renin angiotensin aldosterone system (RAAS): RAAS plays an 
important role in the development of hypertension, cardiovascular 
disease and diabetic nephropathy. Various studies have demonstrated 
the role of angiotensin II (AT II) in the pathology of vascular 
complications of diabetes. Both the tissue RAAS and local RAAS 
play an important role. Local RAAS present in the pancreas and 
adipocytes also contributes to the pathogenesis.  
c) Advanced glycation end(AGE) products: AGE products are formed 
by nonenzymatic reactions between glucose and proteins. The most 
common AGE product is carboxymethyl lysine.
8
 These compounds 
react with specific receptors (RAGE) and interfere with vascular 
signaling, alters the properties of extracellular matrix and alters 
matrix cell interactions of the endothelial cells. AGEs also induce the 
elaboration of growth factors and increase the production of reactive 
oxygen species.
9
 
d) Oxidative stress: It is an imbalance between reactive oxygen species 
and cellular antioxidant mechanisms. Patients with diabetes have a 
decreased levels of intracellular glutathione, which correlates with the 
severity of nephropathy and retinopathy.
10
 Hyperglycemia promotes 
13 
 
oxidative stress through inhibition of pentose phosphate 
pathway(primary source of NADPH), generation of super oxides 
from mitochondria, increasing the activity of vascular NADPH 
oxidase and inhibiting NO mediated endothelial function. 
e) Hexosamine pathway and O-linked glycosylation: Diabetes increases 
the activity of hexosamine pathway and post translational 
glycosylation of proteins resulting in elaboration of growth factors.
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f) Activation of protein kinase C (PKC) pathway: Although 12 different 
isoforms of PKC exist, beta 2 isoform of PKC is activated in 
particular especially in the retina and renal glomeruli. Activation of 
vascular PKC results in an impaired endothelium mediated 
vasodilation thus contributing to a pathological microvascular 
change.
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g) Growth factors: The following growth factors may act separately or in 
concert to produce microvascular changes. The important growth 
factors implicated are vascular endothelial growth factor (VEGF), 
platelet derived growth factor (PDGF), transforming growth factor 
beta (TGF beta), connective tissue growth factors and growth 
hormone/insulin like growth factor. 
h) Endothelium derived factors: There occurs an imbalance between the 
vasodilator and vasoconstrictor molecules derived from the 
14 
 
endothelium. In diabetes there is an increased production of 
endothelin (a powerful vasoconstrictor) and decreased production of 
nitric oxide and prostacyclins.
13
 A widespread endothelial 
dysfunction is a prominent feature of diabetes. 
Although our knowledge on the sequence of these pathways is incomplete, 
drugs that target these signaling pathways can reduce microvascular 
complications, in addition to glycemic control which is of prime 
importance. 
DIABETIC NEPHROPATHY 
Diabetic nephropathy occurs in 30- 50% of patients with type 2 diabetes.
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Although the natural history of diabetic nephropathy is less well understood 
in type 2 diabetes, it is estimated that nephropathy develops only after 5 -10 
years of the disease. The incidence of diabetic nephropathy is increasing 
rapidly due to growing pandemic of diabetes. And more patients with 
diabetic nephropathy reach ESRD because the longevity of diabetic patients 
is increased due to availability of better drugs for control of cardiovascular 
risk factors. 
Risk factors for nephropathy 
1. Genetic factors: Familial clustering of diabetic nephropathy and ACE 
polymorphisms suggest the role of genetics. 
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2. Duration of diabetes 
3. Hypertension 
4. Hyperglycemia 
5. Smoking: Smoking causes vasoconstriction, platelet dysfunction and 
coagulation abnormalities which accelerates vascular damage. 
Though the cellular and molecular mechanism of nephropathy has already 
been briefed, two factors which are responsible for progression of a diabetic 
nephropathy require special mention- hypertension and proteinuria. 
Hypertension is not only a consequence of renal damage, but it plays an 
important role in the genesis and progression of nephropathy.  There is a 
significant correlation between blood pressure levels and drop in glomerular 
filtration rate. Proteinuria is an independent and strong predictor of decline 
in renal function. Excessive protein load leads to tubulointerstitial damage 
and contribute to disease progression. A model of how hypertension and 
proteinuria contribute to renal damage is depicted below:15 
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The natural history of type 2 diabetes has a predictable course of events. In 
the initial stages of diabetes, there is glomerular hyperfiltration stage 
characterized by an increase in GFR.  
After a period of 5-10 years, patient starts excreting small amounts of 
protein termed as microalbuminuria. This stage is known as the stage of 
incipient nephropathy.16 Microalbuminuria is defined as excretion of 30- 
Glomerular capillary 
hypertension
Increased glomerular 
permeability to proteins
Increased filtration of 
plasma protein
Increased reabsorption of 
protein and accumulation 
in proximal tubular cells
Release of fibrogenic 
cytokines
Renal scarring
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299 mg/24 hour urine sample or 30-299 µg/mg of creatinine in a spot 
sample. Microalbuminuria is the earliest marker of diabetic nephropathy.  
Once microalbuminuria sets in, the patient develops hypertension and 
progresses over a period of 5- 10 years to macroalbuminuria. 50% of 
individuals with microalbuminuria progress to macroalbuminuria. This 
stage is the stage of overt nephropathy Macroalbuminuria is defined by 
albumin excretion of >300 mg/day or > 300 µg/mg of creatinine.  
Patients who develop macroalbuminuria develop ESRD over a period of 5-7 
years. Although a variety of genetic and physiological markers are available 
to determine which group of patient will progress to overt nephropathy and 
ESRD, till date there is no standard to ascertain this. 
Microalbuminuria in diabetes 
Microalbuminuria is defined as excretion of 30 – 299 mg albumin per 24 
hour in atleast two out of three consecutive non ketotic sterile samples. It 
refers to the amount of albumin which cannot be detected by the 
conventional dipstick methods.
43
 Under normal circumstances the amount of 
albumin excreted in 24 hours is less than 30 mg. 
The pathogenic mechanism of microalbuminuria in diabetes needs to be 
revisited here. Albumin is a negatively charged particle and has a physical 
radius of 3.6 nm. The glomerular basement membrane has pores of the size 
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of 4 nm, but the negative charge of the glomerular basement membrane 
repels the albumin. 
During the early stages of diabetes, the negative charge in the glomerular 
basement membrane is lost due to a loss of heparin sulphate. As a 
consequence, albumin is freely filtered across the basement membrane 
which appears in the urine. As the disease progresses the basement 
membrane architecture is distorted resulting in loss of large molecular 
weight proteins as well.
43
 
The presence of microalbuminuria not only is an early marker of diabetic 
nephropathy but also carries much more significance. Microalbuminuria is 
also a marker of cardiovascular disease and is a predictor of mortality in 
diabetic nephropathy patients.
44
 What is more important is that 
microalbuminuria identifies nephropathy at a stage when it is potentially 
treatable and reversible. Hence estimation of microalbuminuria is of prime 
importance. 
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NATURAL HISTORY OF DIABETIC NEPHROPATHY
43
 
Stage of 
nephropathy 
Glomerular 
filtration 
rate(GFR) 
Urine 
protein 
excretion 
Histopathological 
changes in the 
kidney 
Stage of 
hyperfiltration 
Increases Normal 
Hypertrophy/increased 
kidney volume 
Incipient 
nephropathy 
Normal/increased 
30- 299 
mg/day 
Basement membrane 
thickening 
Overt 
nephropathy 
Decreased 
>300 
mg/day 
Glomerular occlusion 
and mesangial 
expansion 
End stage renal 
disease(ESRD) 
GFR<15 ml/min Present Scarring and fibrosis 
 
It is important to understand the natural history to device treatment 
strategies and prevent the progression of the disease. Once 
macroalbuminuria develops the pathological changes are irreversible. 
Hence, it is important to identify nephropathy at an earlier stage i.e. the 
stage of incipient nephropathy. Once microalbuminuria is identified, it 
should not only be monitored but also aggressively treated. 
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DIABETIC RETINOPATHY 
Diabetic retinopathy is a highly specific vascular complication of type 2 
diabetes. Diabetes is the leading cause of blindness. The duration of diabetes 
is an important risk factor for the development of retinopathy. More than 60 
% of diabetic patients will have some changes of retinopathy after a period 
of 20 years.
17
 
Diabetic retinopathy is classified into two stages: non proliferative diabetic 
retinopathy and proliferative retinopathy. Clinically significant macular 
edema and vitreous hemorrhage are important causes of blindness in a 
patient with diabetic retinopathy. 
The various retinal lesions that are found in a case of diabetic retinopathy 
are: 
a) Micro aneurysms: Micro aneurysms are one of the earliest findings in 
diabetic retinopathy. They are saccular outpouchings of the retinal 
vasculature and occur as a result of endothelial dysfunction. Ruptured 
micro aneurysms lead to intra retinal haemorrhages
18
 
b) Hemorrhages: Hemorrhages may differ in their appearance depending 
on the retinal layer involved. The “dot/blot” hemorrhages are small 
intraretinal hemorrhages which are characteristic of diabetic 
retinopathy. These hemorrhages occur in the deeper layers of the 
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retina. Hemorrhages in the nerve fibre layer result in flame shaped 
hemorrhage. 
c) Intra retinal microvascular abnormalities(IRMA): IRMA s are pre 
existing vessels with new endothelial cell proliferation that act as 
“shunts” through areas of non perfusion. Presence of IRMAs usually 
indicate a severe form of non proliferative retinopathy and carries an 
increased risk of neovascularization. 
d) Venous caliber abnormalities: These include venous beading, 
dilatation and loop formation and indicate early stage of diabetic 
retinopathy. 
e) Retinal neovascularization: Development of new and abnormal 
vessels is a feature of proliferative retinopathy. Neovascularization 
may occur at the disc (NVD) or elsewhere at the retina (NVE). 
Diabetic retinopathy may present as non proliferative retinopathy, 
proliferative retinopathy or macular edema. 
Non proliferative diabetic retinopathy is classified according to the severity 
as:
45
 
a) Mild NPDR: Presence of micro aneurysm 
b) Moderate NPDR: Presence of micro aneurysm or hemorrhage, 
venous beading and IRMA 
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c) Severe NPDR: Hemorrhages or microaneurysms in all 4 quadrants 
or venous beading in atleast 2 quadrants or IRMA in atleast in one 
quadrant. 
d) Very severe NPDR: Presence of 2 or more of the lesions 
categorized as severe NPDR. 
As the severity of the NPDR increases, risk of patient developing 
proliferative retinopathy increases. 
Proliferative diabetic retinopathy (PDR) includes neovascularization (NVD 
or NVE), preretinal or vitreous hemorrhage. Presence of high risk PDR is an 
immediate indication for laser photocoagulation and hence identifying these 
lesions is crucial in saving vision of the patient. 
Clinically significant macular edema (CSME) which is defined as retinal 
thickening within two disc diameters from the centre of macula is a 
potentially treatable lesion. Presence of macular edema indicates there is a 
25% chance of moderate visual loss in the next 3 years. 
DIABETIC NEUROPATHY 
Diabetic neuropathy occurs in about 50% of patients with type 2 diabetes. 
The classification of diabetic neuropathy is primarily based on the clinical 
manifestations. Although several classification systems are available, the 
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simplest and widely used classification divides diabetic neuropathy into 
diffuse or symmetric neuropathies and focal neuropathies.
46
 
Diffuse or symmetric neuropathies include 
1. Distal symmetric sensorimotor polyneuropathy 
2. Autonomic neuropathy 
3. Acute painful neuropathy 
4. Hyperglycemia induced neuropathy 
5. Treatment induced neuropathy 
6. Symmetric proximal lower extremity neuropathy 
7. Chronic inflammatory demyelinating polyneuropathy(CIDP) 
Of these, distal symmetric sensorimotor polyneuropathy is the most 
common type. Foot ulcers and diabetic arthopathy are dreaded 
complications of diabetic neuropathy and hence remain as issues of prime 
interest. 
Autonomic neuropathy can affect cardiovascular system resulting in resting 
tachycardia, orthostatic hypotension and arrhythmias, gastrointestinal 
system resulting in gastroparesis and genitourinary system resulting in 
erectile dysfunction and bladder emptying abnormalities. 
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Focal/multifocal neuropathies include: 
1. Cranial neuropathy  
2. Thoracoabdominal neuropathy  
3. Focal limb neuropathy  
4. Diabetic amyotrophy 
Mononeuropathy represents symptoms along the distribution of a single 
nerve. Mononeuritis multiplex is common among diabetics and refers to 
simultaneous involvement of multiple peripheral nerves. Cranial 
mononeuropathy occurs in diabetic patients with the most commonly 
involved nerve being the third cranial nerve. Diabetic amyotrophy occurs as 
a result of involvement of the lumbar plexus or the femoral nerve and 
presents as severe pain in the hip and thigh associated with weakness of hip 
flexors and extensors 
Having discussed the macrovascular and microvascular complications with 
special emphasis on the pathogenic mechanism of microvascular 
complications, the relationship between the cardiovascular system and 
diabetes is the topic of prime interest. 
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DIABETES AND CARDIOVASCULAR SYSTEM 
The prevalence of cardiovascular disease is higher among type 2 diabetes 
patients. There is a marked increase in the occurrence of myocardial 
infarctions, coronary artery disease, congestive heart failure and peripheral 
arterial disease, which is attributed to the increase in atherosclerosis. The 
incidence of sudden cardiac death is increased by two to three fold in 
diabetic patients. Such is the strength of association between cardiovascular 
disease and diabetes, that American Heart Association has designated 
diabetes as “coronary artery disease equivalent”. 
Diabetes is the seventh leading cause of mortality, with majority of 
mortality occurring due to cardiovascular complications.
19
Overall 
cardiovascular disease which include both coronary artery disease and 
cerebrovascular accidents account for about 65% of the mortality in diabetic 
patients.20 Although there has been a decline in the deaths due to 
cardiovascular disease in the past three decades, the effect of cardiovascular 
mortality in diabetics lags well behind the general population. Identification 
and treating of cardiovascular risk factors gains top priority in improving the 
outcome of type 2 diabetes patients. 
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CARDIOVASCULAR RISK FACTORS IN TYPE 2 DIABETES 
The traditional risk factors which promote atherosclerosis and are associated 
with type 2 diabetes include: 
1. Female sex 
2. Smoking 
3. Reduced physical activity 
4. Hypertension 
5. Abdominal obesity 
6. Dyslipidemia 
Although the traditional risk factors play an important role in the 
development of atherosclerosis in diabetic patients, the cardiovascular 
mortality rate exceeds by 50% the rate predicted by these factors. This 
suggests that nontraditional risk factors such as hyperglycemia, insulin 
resistance and insulin play a pivotal role in contribution to cardiovascular 
disease.47 
A few risk factors of prime importance are discussed below 
Hypertension: 
Hypertension is a common comorbid condition and accounts for nearly 85% 
of excess cardiac risk. Hypertension increases the risk of coronary artery 
disease, stroke, nephropathy and retinopathy. When hypertension coexists 
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with diabetes, the risk of stroke or CVD is increased two fold and the risk 
for developing ESRD is increased five fold
21
. Hypertension in individuals 
with diabetes has characteristic features which include volume expansion, 
increased salt sensitivity, isolated systolic hypertension, loss of the 
nocturnal dipping of blood pressure and pulse, and increased propensity 
towards orthostatic hypotension.
22
 
Dyslipidemia: 
Dyslipidemia is an important risk factor for development of atherosclerosis 
in diabetic patients. The important lipid abnormalities in diabetic patients 
are as follows: 
1. Increased levels of VLDL due to increased hepatic production 
2. Increase in triglycerides due to increased VLDL production and 
decreased catabolism. Lipoprotein lipase activity is reduced in 
diabetics which plays an important role in metabolism of 
triglycerides. 
3. Decreased HDL levels23 
4. LDL levels remain unchanged. But diabetes patients have a 
tendency to form smaller, denser LDL particles, which undergo 
oxidation easily and promote atherosclerosis.
24
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The growing pandemic of obesity has led to the development of a new entity 
“metabolic syndrome”, which includes dyslipidemia, hypertension, diabetes 
and obesity and threatens to increase the cardiovascular mortality. 
Insulin resistance and hyperglycemia 
Insulin resistance is associated with atherogenic factors and procoagulant 
state and thus promotes atherosclerosis even before overt hyperglycemia 
develops.
25
 Insulin resistance is associated with an increase in plasminogen 
activator inhibitor 1(PAI 1) and fibrinogen, both of which favour thrombus 
formation. The duration of insulin resistance is also a critical factor in 
promoting atherosclerosis. Thus insulin sensitivity and atherosclerosis are 
inversely related. 
Serum glucose level is another important risk factor for cardiovascular 
events. The level of chronic hyperglycemia as measured by glycosylated 
hemoglobin (HbA1C) is an independent risk factor for coronary artery 
disease. A 1% increase in HbA1C levels doubles the risk of cardiovascular 
disease.
26
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Risk factors for cardiovascular disease in type 2 diabetes 
DIABETES AND CARDIAC DISEASE 
With enough evidence suggesting an increased number of cardiovascular 
events and their risk factors, we take a closer look of how diabetes 
specifically affects the heart. Diabetes contributes to the following events in 
heart, which are responsible for the increased cardiovascular morbidity and 
mortality.  
1. Coronary artery disease 
2. Congestive cardiac failure 
3. Diabetic cardiomyopathy 
4. Cardiac autonomic neuropathy(CAN) 
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CORONARY ARTERY DISEASE AND DIABETES 
As already mentioned the risk of coronary artery disease is increased two to 
three fold in diabetic patients. Multivessel disease is more common among 
diabetic population than in the general population. Angiographic studies 
performed in diabetic patients either in a setting of acute myocardial 
infarction or an elective angioplasty have confirmed a higher proportion of 
diabetic patients to have a multivessel disease i.e. involvement of two or 
more vessels with more than 75% stenosis
27
. Not only is the number of 
vessels involved in diabetes increased, the distribution of atherosclerotic 
plaques is diffuse and more severe. Various autopsy studies also confirm the 
same.
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Acute coronary syndromes represent a major cause of death in diabetic 
patients. Diabetic patients who develop myocardial infarction have a higher 
mortality both in the acute phase as well as during the long term follow up. 
In hospital mortality rates are two fold higher in diabetic patients, the 
predominant factor being development of cardiogenic shock and congestive 
cardiac failure.
29,30
 The mechanisms that result in a higher incidence of 
cardiogenic shock following an acute coronary event will be discussed later. 
Other possible mechanisms for a poor outcome include increase in the 
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incidence of re-infarction, infarct extension, and recurrent ischemia. 
Diabetic patients tend to have a decreased propensity to form collaterals and 
so re-infarctions and recurrent ischemia are common.
31
 Long term outcome 
following myocardial infarction is also poor in diabetes patients and is 
related to recurrent MI and development of new onset congestive cardiac 
failure. 
Diabetes may also influence treatment outcomes in patients with coronary 
artery disease. Although it is widely believed that thrombolysis may 
increase the risk of ocular bleeding in a diabetic patient with proliferative 
retinopathy, many studies have failed to show an association. Hence, 
thrombolysis should not be deferred even in a setting of proliferative 
retinopathy. Although coronary artery by pass graft (CABG) offers no 
difference in treatment outcomes between diabetics and non diabetics, the 
scenario is not the same with stenting procedures. There is an increased risk 
of restenosis following placement of coronary stents in diabetic population. 
The major mechanism of restenosis is the increased proliferation of smooth 
muscle cells in diabetic population.
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Another important feature of coronary artery disease in diabetic patients is 
its propensity to cause an unrecognized myocardial infarction often referred 
to as “silent ischemia”. Patients may present without any symptoms or may 
present with atypical symptoms. The probable mechanism for a silent 
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ischemia is presence of autonomic neuropathy in diabetics which involves 
sensory supply to the heart.
33
 The hypothesis is supported by the fact that 
angina perceptual threshold i.e. the time interval between onset of ischemic 
changes to onset of pain during exercise testing is prolonged in diabetic 
patients.34 
CONGESTIVE CARDIAC FAILURE AND DIABETES 
It is well established that the prevalence of heart failure is higher among 
diabetic patients. Observations from the Framingham Study suggest that 
diabetes increases the risk of developing heart failure by 2 fold in men and 5 
fold in women. This increase in the prevalence usually parallels the 
prevalence of coronary artery disease. Coronary artery disease remains the 
most common cause of heart failure in the general population and also in 
diabetics. Hypertension remains a major contributor to heart failure second 
only to CAD. It accounts for 24% of cases.35 
CARDIAC AUTONOMIC NEUROPATHY (CAN) 
Cardiac autonomic neuropathy refers to the dysfunction of the autonomic 
system related to the heart.
48
 Cardiac autonomic neuropathy can manifest as 
orthostatic hypotension, resting tachycardia or painless myocardial 
infarction, which has been highlighted earlier. 
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Initially the parasympathetic fibres are affected, resulting in an increased 
sympathetic tone resulting in resting tachycardia. There is also blunting of 
hemodynamic responses to exercise. As a result of the decreased 
parasympathetic tone, coronary vasoconstriction occurs, which results in 
ischemia.  
CAN significantly contributes to cardiovascular morbidity and mortality. 
The possible mechanisms are  
1. Increased risk of ventricular arrhythmias due to perturbations in 
the rhythm. As a consequence, diabetic patients with CAN are at 
an increased risk of sudden cardiac death. 
2.  Increased resting heart which increases the myocardial oxygen 
demand. 
3. Silent myocardial ischemia. 
4. Impaired vasomotor regulation. 
Presence of CAN indicates a poor prognosis to the underlying cardiac 
disorder. CAN is detected by measuring the heart rate variability over a 24 
hour period, QT interval and QT dispersion.
36
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DIABETIC CARDIOMYOPATHY 
Whether factors other than coronary artery disease and hypertension can 
result in heart failure in diabetics remain a controversial subject and an area 
of potential research. 
Diabetic cardiomyopathy refers to presence of dilated cardiomyopathy in 
diabetic patients in the absence of coronary artery disease, hypertension and 
valvular heart disease.
44
 
 The concept of diabetic cardiomyopathy was first proposed by Rubler et al 
in 1972
49
. Later Regan et al
50
 demonstrated increased left ventricular filling 
pressures in normotensive diabetic patients free of symptoms of heart 
failure. Abnormalities in diastolic function with an intact systolic function 
were demonstrated by Raev et al. Various studies on clinical subjects and 
postmortem studies suggested the possibility of existence of idiopathic 
cardiomyopathy associated with diabetes.  
Diabetic cardiomyopathy may not present with florid symptoms of failure 
but its presence can be assessed by subtle changes in imaging. Although 
most studies were performed on type 1 diabetics, data is available for type 2 
diabetes patients also. 
The existence of diabetic cardiomyopathy remains controversial. To confirm 
its presence and its potential role in worsening cardiovascular outcome in 
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diabetic patients, a thorough understanding of heart failure, methods of 
detection and underlying pathogenic mechanisms is needed. 
HEART FAILURE AND ITS TYPES 
Heart failure, in simple terms, is the inability of the heart to meet with the 
metabolic needs of the tissues. Although there are several ways to classify 
heart failure, the most scientific classification relevant to this topic would be 
to divide it into systolic heart failure and diastolic heart failure. This 
classification is purely based on echocardiographic parameters. 
An important parameter is assessment of heart failure while performing an 
echocardiography is ejection fraction. Ejection fraction is defined as fraction 
of blood pumped out of the ventricle during each cardiac cycle. 
Ejection fraction = (End diastolic volume – end systolic volume)/end 
diastolic volume 
Normal ejection fraction ranges between 55-70%. 
Systolic failure is defined as heart failure with reduced ejection fraction  (< 
40%) i.e. failure of contraction of ventricles, in which case there is 
decreased amount of blood available to carry adequate oxygen and nutrients 
to the tissues. Diastolic heart failure is defined as heart failure with 
preserved ejection fraction (40-50%).i.e. failure of ventricles to relax.  
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DIASTOLIC HEART FAILURE
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Diastole or the relaxation phase of the ventricle, begins with the aortic 
closure and ends with mitral closure. 
The diastole, like the systole is an active process and comprises of four 
phases:52 
1. Isovolumetric relaxation time: In this phase, both aortic and mitral 
valves remain closed and there is no flow of blood from atrium to 
ventricle in this phase. 
2. Early filling period: The mitral valve opens and the left atrium 
empties into the left ventricle, which represents about 80% of the 
diastolic flow. The early filling period velocity is denoted by E. 
3. Diastasis: The pressures on the left atrium and ventricle are 
equilibrated and there is very little flow during this phase. 
4. Atrial contraction: The atrium contracts resulting in flow of blood 
into the ventricle representing 15% of diastolic flow. The velocity 
in this phase is denoted by A. 
Under normal conditions, E velocity is larger than A velocity and hence E/A 
ratio is more than 1. In pathological states associated with abnormal 
relaxation of the ventricle, there is an increase of flow during the atrial 
contraction phase to about 25-30%, producing reversal of E/A ratio. 
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Diastolic heart failure is a clinical syndrome, whereas diastolic dysfunction 
is a mechanical abnormality of diastole of the heart with or without clinical 
symptoms. Diastolic dysfunction can occur is isolation or in combination 
with systolic dysfunction. 
Any abnormality in the left ventricular relaxation or its compliance alters 
the onset, rate and extent of left ventricular pressure decline. These 
abnormalities disrupt the normal relationship between left ventricular 
pressure and volume. As a consequence, the filling pressures increase in 
order to maintain a normal left ventricular end diastolic volume.
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During exercise and tachycardia, these filling pressures are increased further 
resulting in exertional dyspnea and fatigue. 
The various causes of diastolic dysfunction are: 
1. Cardiac conditions: Cardiomyopathies of restrictive and 
hypertrophic type result in diastolic dysfunction. Constrictive 
pericarditis also results in diastolic failure 
2. Hypertension: Hypertension results in a left ventricular 
hypertrophy which interferes with normal relaxation. 
3. Ischemic heart disease: It is usually associated with systolic 
dysfunction. 
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4. Old age: As the age increases, the myocardium loses its elastic 
properties and results in impaired relaxation 
5.  Obesity 
6. Diabetes  
Assessment of diastolic function and grading 
As the symptoms produced by systolic and diastolic do not differ much 
except for the frequency of occurrence, it is difficult to differentiate between 
them on clinical grounds. Hence, invasive or non invasive methods are 
employed to assess the diastolic function. 
Cardiac catheterization is the gold standard for assessing diastolic 
dysfunction. Because of its invasive nature, it cannot be performed in all 
individuals and hence its utility is limited in terms of assessing diastolic 
dysfunction. 
Echocardiography is the most widely used imaging modality to assess the 
diastolic function. It is a non invasive technique and easily available tool. 
Doppler echocardiography is commonly employed to assess and grade the 
diastolic dysfunction.  
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Various parameters like: 
1.  E wave velocity (velocity of flow during early filling phase),  
2. A wave velocity (velocity of flow during atrial contraction), 
3.  E wave deceleration time (EDT)( time interval between the peak 
of E wave to zero) 
4.  Isovolumetric relaxation time (IVRT) are measured 
Doppler study of the pulmonary vasculature yields additional paramaters 
like S wave velocity, D wave velocity, S/D ratio and atrial reversal (AR). 
These parameters are used either in single or in combination to assess and 
grade diastolic dysfunction.53 
Echocardiographic parameters to assess diastolic function 
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Diastolic dysfunction presents in four patterns:
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Grade I: (Abnormal relaxation pattern) 
Characterized by a decreased E wave velocity and increased A wave 
velocity. E/A ratio < 1; Increased IVRT (>100ms); Increased EDT (>240 
ms); S/D ratio>1; AR < 35 cm/s. Patients with grade I diastolic dysfunction 
have no symptoms at rest but have mild exercise limitation. 
Grade II (Pseudonormal pattern): 
The normal LV filling pattern is maintained i.e. E/A ratio >1. But LV filling 
pressures are increased, evidenced by increased AR velocity. Abnormal 
relaxation pattern is observed during Valsalva maneuver. Patients have 
exertional dyspnea and moderate functional impairment  
Grade III (Reversible restriction): 
Characterized by E/A ratio>2.5; decreased EDT (< 150 ms); decreased 
IVRT (<70 ms); S/D ratio < 1; AR >35 cm/s. These findings are reversible 
with Valsalva. Patients have dyspnea with mild exertion and marked 
functional impairment. 
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Grade IV (Irreversible restriction): 
Features of restrictive pattern which are not reversed by Valsalva are 
present. 
Other techniques like ventriculography and cardiac catheterization may be 
used to assess the diastolic dysfunction.  
Schematic diagram of diastolic dysfunction(in echocardiography) 
 
Grade of diastolic 
dysfunction 
Pathological abnormality 
Echocardiographic 
parameters 
Grade I Impaired relaxation E/A ratio < 1 
Grade II 
Impaired relaxation and 
compliance 
E/A ratio>1 with 
increased left atrial 
pressures 
Grade III 
Restrictive 
filling(reversible) 
E/A ratio > 2.5 and 
elevated ventricular 
filling pressures 
Grade IV 
Restrictive filling 
(irreversible) 
Same as grade III with 
irreversible changes 
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DIASTOLIC DYSFUNCTION IN DIABETES 
Diastolic dysfunction is a pre runner of heart failure in diabetic patients.
54
 It 
is also an independent risk factor for all-cause mortality. The cardiovascular 
outcome worsens with increasing severity of diastolic dysfunction. Diastolic 
dysfunction can occur in isolation without co existent systolic function. 
The importance of diastolic dysfunction is emphasized by the fact that 
diabetic patients are associated with increased risk of heart failure and 
cardiogenic shock following a myocardial infarction. Observations from 
various studies highlight the following facts: 
1. Studies using serial estimations of cardiac enzymes and 
echocardiography have found no evidence that patients with 
diabetes sustain more extensive infarctions than their nondiabetic 
counterparts.
37
 
2.  Cardiogenic shock  and heart failure are out of proportion to the 
index infarct size in diabetic patients. 
3. Clinical manifestations of heart failure occur in patients with 
diabetes despite a modest drop in the ejection fraction (EF).
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These observations suggest the possibility of preexisting diastolic 
dysfunction as a major contributor to the adverse outcomes. Subclinical 
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diabetic cardiomyopathy, which is characterized by diastolic dysfunction, is 
a likely possibility.
39 
Diastolic dysfunction in diabetic patients may also influence exercise 
capacity as evidenced by a reduced maximal capacity during treadmill.63,64 
The presence of diastolic dysfunction was confirmed later by variety of 
observations. Framingham study reported increased incidence of heart 
failure among diabetic patients even after adjustment for confounding 
variables.
40
 Washington cardiomyopathy study also confirmed the 
association between diabetes and idiopathic cardiomyopathy. 
Echocardiographic studies performed later also confirmed the existence of 
diastolic filling abnormalities in diabetic patients.
41,42
 All these data suggest 
that diabetes could be a cause for diastolic dysfunction even in the absence 
of systolic dysfunction.  
Studies (Takenaka et al.(1988), Hiramatsu et al.(1992),Annonu et al(2001))  
performed in diabetic patients free of coronary artery disease and 
hypertension, have demonstrated that patients  exhibited LV diastolic 
dysfunction. 
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Mechanisms of diastolic dysfunction in diabetes:
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Although the exact pathogenesis of diastolic dysfunction remains unknown, 
various molecular mechanisms have been proposed. The most important 
mechanisms being: 
1) Metabolic disturbances: Diabetic hearts have a blunted response to 
the uptake of insulin mediated uptake of glucose. There is an 
increased utilization of free fatty acids, which can result in cardiac 
dysfunction. Ketoacids, the production of which is increased in 
diabetes is taken by the cardiac myocytes, which in turn reduces 
coenzyme A and citric acid cycle and produces myocardial 
dysfunction. Abnormalities in calcium homeostasis results in 
activation of the PKC signaling pathways and result in cardiac 
dysfunction. Insulin resistance may also mediate cardiac 
dysfunction. 
2) Myocardial fibrosis: Diabetic hearts have demonstrated myocyte 
hypertrophy, perivascular fibrosis and increased quantities of 
matrix collagen. It is attributed to the accumulation of advance 
glycation end products (AGE). 
3) Small vessel disease: Endothelial dysfunction, oxidative stress and 
impaired coronary reserve contribute to a small vessel disease. 
4) Cardiac autonomic neuropathy 
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 Factors contributing to diastolic dysfunction 
When observed carefully, there is a considerable overlap between the 
mechanisms proposed for microvascular complications and diastolic 
dysfunction. It is also postulated that the severity of diastolic dysfunction 
parallels the severity of microvascular complications. 
 Heart disease in diabetes is primarily due to macrovascular disease, but 
growing evidence from different observations suggesting the possibility of a 
microvascular diabetic heart is gaining more importance. With diabetic 
therapies being targeted at molecular and cellular levels, cardiac dysfunction 
in diabetics can be curtailed if not prevented. 
  
Diastolic 
dysfunction
Oxidative 
stress 
Endothelial 
dysfunction
Advanced 
glycation end 
products 
Hyperglycemia
Increased free 
fatty acids 
Altered 
calcium 
homeostasis
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MATERIALS AND METHODS: 
STUDY DESIGN 
Cross sectional study 
 
SAMPLE 
Diabetic patients from Institute of Internal Medicine and Institute of 
Diabetology, Rajiv Gandhi Government General Hospital were enrolled in 
the study. Around 60 patients were enrolled for the study after informed 
consent from all patients. Institutional ethical clearance was obtained. 
Patients were selected based upon the following inclusion and exclusion 
criteria. 
INCLUSION CRITERIA: 
• Known case of type 2 diabetes mellitus patients 
• Newly diagnosed type 2 diabetes mellitus patients 
• Age group >30 years. 
Patients who were already on drugs for diabetes either in the form of insulin 
or OHAs were included. Newly diagnosed patients (patients who had 
symptoms of diabetes along with a random blood sugar >200mg/dl or 
fasting plasma glucose >126 mg/dl) were also included in the study. Age 
group of more than 30 years was used to avoid overlap of type 1 and other 
forms of diabetes mellitus.  
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EXCLUSION CRITERIA: 
• Pregnant women 
• Hypertensive patients 
• Known coronary artery disease patients 
• Known valvular heart disease, arrhythmias 
• Other co morbidities(COPD, pre-existing renal disease, thyroid 
disorders) 
METHODOLOGY 
After informed consent from the enrolled patients, a questionnaire was 
prepared to obtain details of the patient’s address, sex, age, occupation and 
symptoms if any. History of diabetes, its duration, drug history and potential 
complications were given special importance. The patient’s vital parameters 
were recorded. Patient’s height and weight were measured to estimate the 
body mass index (BMI). The body mass index was calculated using the 
formula.  
Body mass index (BMI) = Weight of the patient (in kg)/ (height)
2 
(in m
2
) 
Routine examination of the patient was done. Ophthalmoscopic evaluation 
was done using the direct ophthalmoscope. Diabetic retinopathy if present 
was identified and classified non proliferative retinopathy (NPDR) and 
proliferative retinopathy (PDR). 
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Patients were subject to laboratory investigations like complete blood 
counts, renal function tests, fasting and postprandial blood sugar levels and 
fasting lipid profile. 
Diabetic nephropathy was assessed in the patient by measuring the renal 
parameters (blood urea and serum creatinine). Urine routine and cultures 
were done to exclude a urinary tract infection. Proteinuria was assessed in 
all patients. Ultrasonogram of kidneys was done when required. 
MEASUREMENT OF MICROALBUMINURIA:
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Microalbuminuria is estimated by a 24 hour urine collection or a spot urine 
sample. While collecting the sample, following precautions are taken: the 
patient should be at rest; patient should be free of ketosis; and glycemic 
status should be fairly under control. 
When 24 hour urine samples are used for estimation, excretion of 30- 299 
mg/day is considered as microalbuminuria. 
Alternatively, estimation of urine albumin excretion rate(AER) or spot urine 
estimation of albumin to creatinine ratio(ACR) is used. The spot sample is 
preferred as it is the convenient method in clinical practice. Urine albumin 
excretion rate (AER) of 20- 200 micro g/min signifies microalbuminuria. 
Normal values are less than 20 micro g/min. Urine albumin to creatinine 
ratio (ACR) of less than 30 micro g/mg of creatinine is normal. 
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30 – 299 micro g/ mg signifies microalbuminuria. Values more than 300 
indicate overt nephropathy or macroalbuminuria. 
The various methods by which microalbuminuria can be estimated are: 
1. Microalbumin urine test strips: Employs immunochemical strips 
which are specific for albumin. 
2. Radio immunoassay: This technique is highly sensitive and has 
good accuracy but carries the disadvantage of radioactivity. 
3. Radio immunodiffusion: This method requires long incubation 
period and hence is not widely accepted. 
4. ELISA: Competitive and sandwich ELISA techniques are 
employed for quantification of albumin. 
5. Immunoturbidometry: Quantifies the amount of albumin based on 
spectrophotometric analysis and is suitable for analyzing large 
number of samples at a faster rate. 
Causes for false positive tests: 
Transient increases in urine albumin excretion may occur in a setting of  
1. Short term hyperglycemia  
2. Fever 
3. Urinary tract infections  
4. Marked hypertension 
5. Cardiac failure  
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6. Contamination with seminal or menstrual fluid 
7. Following exercise 
In our patients, microalbuminuria was estimated in a spot urine sample 
using photometric techniques by the method of fully automated 
immunoturbidometry. The above mentioned causes were excluded in the 
patient before estimating urine albumin excretion. Urine creatinine was also 
estimated and urine albumin to creatinine ratio was calculated to reduce 
errors due to intraindividual variability in albumin excretion 
The following reference values were used: 
Urine creatinine  :    In males: 39-259 mg/dl 
      In females: 28-217 mg/dl  
Normal ACR   :  < 30 microgram /mg of creatinine. 
 
ASSESSMENT OF DIASTOLIC DYSFUNCTION: 
All the patients enrolled in the study were subjected to Echocardiography. 
Transthoracic echocardiography was done after clinical evaluation. 
2D echocardiography was done to assess the ventricular dimensions, 
presence of regional wall motion abnormalities and left ventricular ejection 
fraction. The parasternal long axis and short axis views were used. The 
ejection fraction was obtained using Simpson’s approach. 
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Doppler echocardiography was done and using the apical four chamber 
view. The transmitral velocities were obtained by positioning the sample 
volume at the level of the tips of mitral leaflets. The early mitral inflow 
velocity (E) and late inflow velocity (A) was obtained and E/A ratio was 
calculated.  
 
Doppler ECHO:  Measurement of E velocity and A velocity 
E/A ratio of less than 1 was considered grade 1 diastolic dysfunction. When 
E/A ratio was more than 1, additional parameters like the velocity 
propagation, E wave deceleration time were considered to differentiate 
Grade II diastolic dysfunction from a normal pattern. The velocity 
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propagation of the early mitral inflow was assessed using a colour M mode 
echocardiography.  
Data obtained by above methods was analysed statistically using  
1. SPSS 15 
2. Chi square test
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OBSERVATIONS AND RESULTS 
PATIENT CHARACTERISTICS: 
Sex Distribution: 
Among the 60 patients enrolled in the study, 34 were male patients and 26 
were female patients. 
Table 1: Sex distribution 
Sex No. of patients (n=60) Percentage 
Males 34 56.67% 
Females 26 43.33% 
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57%
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43%
SEX DISTRIBUTION
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Age distribution 
Only patients above the age of 30 years were included in the study. Patients 
were evenly distributed with respect to age characteristics. Maximum 
number of patients was in the age group 50 -59 years (18 patients). 13 
patients were above the age of 60 years. The mean age in our study was 
49.3±10.4.  
Table 2: Age distribution 
Age distribution No. of patients(n=60) 
30-39 years 15 
40-49 years 14 
50-59 years 18 
60 and above 13 
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Duration of diabetes 
With respect to duration of diabetes, patients were evenly distributed. 
Maximum number of patients was in the subcategory of 0-4 years duration 
(23 patients out of 60). Mean duration of diabetes in our study was 6.07 
years ±4.9. 
Table 3: Duration of diabetes 
Duration of diabetes No. of patients (n=60) 
0-4 years 23 
5-9 years 20 
10 years and above 17 
 
 
Treatment modality of diabetes 
Among the 60 patients, 34 were on oral hypoglycemic agents, 11were 
receiving insulin and 6 of them received both forms of therapy. 9 patients 
were newly diagnosed and yet to be started on treatment. 
Table 4: Treatment of diabetes 
Treatment modality No of patients (n=60) 
Oral hypoglycemic agents(OHA) 34 
Insulin 11 
OHA and insulin 6 
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Distribution of BMI (body mass index) 
Patients were stratified on the basis of their BMI. Most patients (35 patients 
out of 60) had a BMI value between 25 and 29.9. 10 patients were obese 
(BMI > 30 kg/m2). None of the patients in our study had morbid obesity. 
The mean BMI value in our study was 26.58±2.78. 
Table 5: Body mass index 
BMI Values(in kg/m
2
) No. of patients (n=60) 
< 24.9 15 
25- 29.9 35 
>30 10 
 
Triglyceride levels 
54 out of 60 patients had triglyceride levels more than 150 mg/dl, out of 
which 13 of them had values above 250mg/dl. The mean triglyceride level 
value in our study was 210.43±60.09. 
Table 6: Triglyceride level distribution 
Triglyceride level (mg/dl) No. of patients (n=60) 
<150 6 
150- 200 27 
200-249 14 
>250 13 
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Retinopathy in diabetes 
Among the 60 patients, 31 patients (51.67%) had retinopathy of which 26 of 
them had non proliferative retinopathy and 5 patients had proliferative 
retinopathy. 
Table 7: Retinopathy in diabetes 
Type of retinopathy No. of patients (n = 31) 
Non proliferative diabetic 
retinopathy 
26 
Proliferative retinopathy 5 
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Table 8: Retinopathy distribution with respect to duration 
Duration of diabetes 
No. of patients with 
retinopathy (n=31) 
NPDR PDR 
0-4 years 1 0 
5-9 years 13 1 
10 years and above 12 4 
 
Out of the 31 patients with retinopathy, 16 patients had diabetes for 10 years 
or more. The prevalence was very low when the duration of diabetes was 
less than 5 years. 
Out of 5 patients with proliferative retinopathy, 4 of them had diabetes for 
10 years or longer.  
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Nephropathy in diabetes 
40 patients out of 60 had evidence of nephropathy in the form of 
proteinuria. Microalbuminuria was present in 34 patients and overt 
nephropathy (macroalbuminuria) was present in 6 patients. 
Table 9: Nephropathy in diabetes 
Nephropathy No. of patients (n=40) 
Microalbuminuria 34 
Macroalbuminuria 6 
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 Table 10: Diabetes duration and nephropathy  
Duration of diabetes 
No. of patients with nephropathy 
(n=40) 
Microalbuminuria Macroalbuminuria 
0-4 years 10 0 
5-9 years 13 2 
10 years and above 11 4 
 
The prevalence of nephropathy was considerably higher when the duration 
of diabetes was more than 5 years. Nearly 62.5% of patients with 
proteinuria had diabetes for more than 5 years.  
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Microvascular complications 
The overall prevalence of retinopathy in our study was 51.6% and that of 
nephropathy was 66.67%. 
Microalbuminuria was present in 56.6% of cases. 
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Prevalence of diastolic dysfunction 
Among the 60 patients of type 2 diabetes, 34 of them had evidence for 
diastolic dysfunction. 32 of these patients had Grade I diastolic dysfunction 
and 2 of them had Grade II diastolic dysfunction. Grade III and Grade IV 
dysfunction were not observed in our study.  
The mean E/A ratio in our study was 1.047±0.356. In patients with diastolic 
dysfunction the E/A ratio was much lower (0.7701±0.09) than patients with 
normal function (1.326±0.24) (p<0.001**). 
. 
 
The above mentioned patients had isolated diastolic dysfunction. Patients 
having associated systolic dysfunction were excluded from the study 
population. None of these patients had clinical evidence for heart failure. 
Age distribution 
NORMAL 
FUNCTION
(43%)
DIASTOLIC 
DYSFUNCTION
(57%)
PREVALENCE OF DIASTOLIC DYSFUNCTION
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The prevalence of diastolic dysfunction increases with age. The highest 
percentage of patients having isolated diastolic dysfunction was in the 60 
and above age group. (12 out 13 patients) 
Table 11: Diastolic dysfunction and age distribution 
Age group (n=60) 
No. of patients with 
diastolic 
dysfunction (n=34) 
% of patients of  
diastolic 
dysfunction 
Grade I Grade II 
30-39 years (n= 15) 3 0 20% 
40-49 years(n= 14) 7 0 50% 
50 -59 years(n= 18) 11 1 66.7% 
60 years and above(n= 13) 11 1 92.3% 
 
By Pearson Chi square test, for the above values p value = 0.010**, 
significant at 1% level.  
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Diastolic dysfunction and sex 
Out of 34 male patients, 18(52.9%) had diastolic dysfunction and among 
26 females, 16 (62.5%) had diastolic dysfunction. 
Table  11: Diastolic dysfunction and sex 
Sex  (n=60) 
No. of patients with 
diastolic dysfunction 
(n=34) 
% of patients of  
diastolic 
dysfunction 
Grade I Grade II 
Male (n=34 ) 16 2 52.9% 
Female (n= 26) 16 0 62.5% 
 
 By Pearson Chi square test P value =0.307, statistically not significant  
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Males Females
D
IA
S
T
O
LI
C
 D
Y
S
F
U
N
C
T
IO
N
DIASTOLIC DYSFUNCTION -
SEX DISTRIBUTION
65 
 
Diastolic dysfunction and duration of diabetes 
In our study, the prevalence was 88.3%, when the duration of diabetes was 
more than 10 years. The prevalence of diabetes increased steadily with 
increasing duration. Our study did not compare the diastolic dysfunction 
with respect to severity of diabetes. 
Table 12: Diastolic dysfunction and duration of diabetes 
Duration of 
diabetes(n=60) 
No. of patients with 
diastolic dysfunction 
(n=34) 
% of patients of  
diastolic 
dysfunction 
Grade I Grade II 
0 – 4  years (n= 23) 5 0 21.7% 
5- 9 years(n= 20) 13 1 70.0% 
10 years and above(n=17 ) 14 1 88.3% 
 
By Chi square test, p value = 0.001**, significant at 1 % level. 
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Diastolic dysfunction and obesity 
In our study, positive correlation for obesity is as high as 70%, when the 
BMI value is more than 30, suggesting a very strong association between 
obesity and diastolic dysfunction. 
Table 13: Diastolic dysfunction and obesity 
Body mass index(n=60) 
No. of patients with 
diastolic dysfunction 
(n=34) 
% of patients of  
diastolic 
dysfunction 
Grade I Grade II 
< 25(n= 15) 4 0 26.7% 
25- 29.9(n= 35) 23 0 65.7% 
30 and above(n=10) 5 2 70% 
 
By Pearson Chi square test, p value = 0.002**, significant at 1% level. 
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Diastolic dysfunction and triglyceride levels: 
Since the most common abnormality in lipid profile in a diabetic patient is 
triglyceride increase, we tried to find out the correlation between 
triglyceride level and diastolic dysfunction. 
 Table 14: Diastolic dysfunction and triglyceride levels  
Triglyceride 
levels(n=60) 
No. of patients with 
diastolic dysfunction 
(n=34) 
% of patients of  
diastolic 
dysfunction 
Grade I Grade II 
< 150 mg/dl (n= 6) 0 0 0% 
150- 199 mg/dl(n= 27) 19 0 70.4% 
200-249 mg/dl(n= 14) 8 1 64.2% 
>250 mg dl(n= 13) 5 1 46.2% 
By Pearson chi square test, p= 0.032*, significant at 5% level. 
In our study, highest percentage of diastolic dysfunction was observed in 
the 150 -199 mg/ dl age group around 70%. Patients with triglyceride 
levels less than 150 mg/dl showed no diastolic abnormalities. 
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Diastolic dysfunction and treatment modality 
As per our study, patients receiving insulin alone or in combination with a 
oral hypoglycemic agents had a higher prevalence of diastolic 
dysfunction.  
Table 15: Diastolic dysfunction and treatment modality 
Treatment 
modality(n=51) 
No. of patients with 
diastolic dysfunction 
(n=34) 
% of patients of  
diastolic 
dysfunction 
Grade I Grade II 
OHAs (n= 34) 17 2 55.9% 
           Insulin (n= 11) 10 0 90.9% 
OHAs/Insulin(n= 6) 5 0 83.3% 
 
By Pearson chi square test, p= 0.121, statistically not significant. 
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Diastolic dysfunction and retinopathy 
Out of 31 patients with retinopathy, 26(83.8%) had diastolic dysfunction. 
The proportion of patients with diastolic dysfunction was higher for 
proliferative retinopathy. All 5 patients with proliferative retinopathy had 
diastolic dysfunction. 
Table 16: Diastolic dysfunction and retinopathy 
Retinopathy  
No. of patients with 
diastolic dysfunction 
(n=26) 
% of patients of  
diastolic 
dysfunction 
Grade I Grade II 
Non proliferative 
retinopathy(n= 26) 
19 2 80.8% 
Proliferative 
retinopathy(n = 5) 
5 0 100% 
Total (n=31) 24 2 83.8% 
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Table 17: Retinopathy and Diastolic Dysfunction 
Retinopathy 
No. of patients(n=60) 
Total no. of 
patients 
Normal 
diastolic 
function 
Diastolic 
dysfunction 
No retinopathy 21 8 
29 
Retinopathy 5 26 
31 
 
Chi square test values for the above data: p value<0.001** 
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Diastolic dysfunction and nephropathy 
Among 40 patients with nephropathy, 32 of them had diastolic dysfunction 
accounting for 80%. The association with macroalbuminuria was 
significantly higher with all 6 patients developing diastolic dysfunction. 
Table 18 : Diastolic dysfunction and nephropathy 
Nephropathy   
No. of patients with 
diastolic dysfunction 
(n=26) 
% of patients of  
diastolic 
dysfunction 
Grade I Grade II 
Microalbuminuria (n= 34) 25 1 76.5% 
Macroalbumuria (n = 6) 5 1 100% 
Total (n=40) 30 2 80.0% 
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Table 19: Diastolic dysfunction and nephropathy 
Nephropathy 
No. of patients (n=60) 
Total no. of patients Normal 
diastolic 
function 
Diastolic 
dysfunction 
No nephropathy 18 2 20 
Nephropathy  8 32 
40 
 
By Chi square test value: p <0.001** 
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DISCUSSION 
Diastolic dysfunction in diabetes: 
As per our study, 57 % of type 2 diabetes had diastolic dysfunction. Khalil S 
I et al. (2007)
56
 estimated that about 58% of diabetic patients had diastolic 
dysfunction of which majority of them were Grade I diastolic dysfunction. 
Cosson et al (2003)
44
 demonstrated 69% of diabetics have abnormalities in 
diastolic filling.  
However, the prevalence may vary among different population and study 
groups because of the different parameters employed in Doppler 
echocardiography is assessing the diastolic function. Although E/A ratio is 
the commonly employed parameter, higher grades of diastolic dysfunction 
tend to be missed out if additional parameters or specific maneuvres are 
employed. Cosson et al (2003)
 44
 reported around 20% increase in the 
prevalence if additional parameters are employed. In our study we have 
employed propagation velocity and E wave decelaration time in identifying 
the pseudonormal pattern (Grade II dysfunction). 
Freire et al. (2007)
52
 estimated the prevalence of asymptomatic isolate 
diastolic dysfunction in the general population to be 27%. 
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Diastolic dysfunction and age: 
As per our study, increasing age is a risk factor in diabetes for diastolic 
dysfunction. With almost 70% patients with diastolic dysfunction above the 
age of 50 years, it is quite clear that age is directly proportional to the 
prevalence of diastolic dysfunction. 
Srivastava et al.(2006)
 57
 confirmed that increasing age is an independent 
predictor for both cardiac dysfunction and diastolic dysfunction in type 2 
diabetic patients. The mean age of patients in the study was 60 ± 1.  
Khalil S I et al (2007)
 56
 also demonstrated that age is an important risk factor 
for diastolic dysfunction in type 2 diabetes. In the study, prevalence of 
diastolic dysfunction in the age group 41-50 years was around 80% compared 
to 12.5% in the 21- 30 year age group. The mean age of the study group was 
40.79± 7.65 years. 
Diastolic dysfunction and sex: 
Although our study demonstrates a higher prevalence among females, it was 
statistically not significant and underlying causes or mechanisms are not 
available to substantiate the discrepancy. 
R. Wachter et al (2007)
55
 shows that the presence of diabetes mellitus has an 
influence on diastolic function in males but there was no difference in 
females between the diabetic and non- diabetic population. Non diabetic 
males showed a lower prevalence (58.9%) of impaired relaxation compared 
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to those with diabetes (69.7%). The presence of coexisting coronary artery 
disease did not change the outcome. 
Diastolic dysfunction and duration of diabetes: 
High statistical significance (p = 0.001**) was observed for the association 
between duration of diabetes and diastolic dysfunction 
Data from Khalil S I et al (2007)
 56
 show that the prevalence of diastolic 
dysfunction increases with duration of diabetes. The study demonstrates a 
100% prevalence of diastolic dysfunction when the duration of diabetes was 
more than 10 years. In our study, the prevalence was 88.3% in the same age 
group. In a study by Raev et al.
59
, diastolic dysfunction started at 8 years after 
the onset of diabetes. 
R. Wachter et al (2007)
55
 failed to demonstrate a positive correlation between 
duration of diabetes and diastolic dysfunction, but showed a significant 
difference when analysed with respect to severity of diabetes. According to 
the study, patients with HbA1C >8 % had a higher prevalence of diastolic 
dysfunction (92.9%). Freire et al (2007)
52
 also confirmed the presence of 
diastolic dysfunction in patients with HbA1C more than 8%. For every 1% 
increase in HbA1C, there is 8% increase in the risk of developing heart 
failure. 
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Diastolic dysfunction and obesity: 
Obesity as defined by BMI > 30 kg/m
2 
was present in 16.6% of patients. 
Srivastava et al (2006)
 57
 showed data that a little over 50 % of the study 
population was obese. Obesity in the above study was defined by value of 
BMI > 30 kg/m2.  Patients with a BMI > 30 kg/m2 had a significant increase 
in cardiac dysfunction and diastolic dysfunction as per the study. Although, 
the prevalence of obesity was comparatively lower in our study, the risk of 
diastolic dysfunction in obese individuals had comparable results. 
Diastolic dysfunction and treatment modality: 
Though our study demonstrated a higher prevalence of diastolic dysfunction 
in patients receiving insulin, it was statistically not significant.  
However, hyperinsulinemia is a potential pathogenic mechanism implicated 
in diabetic cardiomyopathy. But it remains unclear whether exogenous 
insulin have the same effect as that of endogenous insulins. There are also 
other confounding factors like hyperglycemia, which would have necessitated 
the use of insulin. 
Hence these results should be interpreted with caution and it does not 
preclude the use of insulin. Further studies on a larger scale are required for 
its confirmation. 
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Diastolic dysfunction and lipid profile: 
Diastolic dysfunction was highest in the 150-199 mg/ dl group. But isolated 
measurement of triglyceride alone is not recommended. A complete lipid 
profile is needed to contemplate further results.  
Khalil S I et al (2007)
56
 showed no association between lipid profile and 
diastolic dysfunction.  
Diastolic dysfunction and retinopathy: 
It is known that 60% of patients with type 2 diabetics develop retinopathy at 
the end of 20 years. In our study, nearly 50% of patients showed evidence for 
retinopathy, the mean duration of diabetes in our study being 6.07 years. 
The association between retinopathy and diastolic dysfunction had strong 
correlation in our study (p<0.001**). Patients with proliferative retinopathy 
had a stronger association. 
Takenaka et al (1988)58 demonstrated an association between retinopathy and 
type 2 diabetic patients free from coronary artery disease and hypertension. 
Annonu et al (2001)
60
 demonstrated that E/A ratio < 1 in 49 % of patients 
with retinopathy. 
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Diastolic dysfunction and nephropathy: 
The prevalence of microalbuminuria in our study was 56.6%, compared to 
other Indian data, which report a prevalence of around 30%. A considerable 
number of patients with diabetic duration < 5 years had microalbuminuria (10 
patients). End stage renal disease was not observed in our study because 
hypertensive patients were excluded from the study and most ESRD patients 
would have associated hypertension. Though all possible causes of false 
elevation of microalbuminuria were excluded, it requires confirmation with 
serial measurements. 
However, the association between nephropathy and diastolic dysfunction is 
strong in our study (p<0.001**). 
Although various studies done in type 1diabetes suggest an association 
between albuminuria and diastolic dysfunction, study done in type 2 diabetes 
by Annonu et al (2001)60 failed to demonstrate a significant association. 
The association of diastolic dysfunction with microvascular complications 
strongly suggests the possibility of a background microangiopathy. Since 
microalbuminuria is also marker of endothelial dysfunction, diastolic 
dysfunction indicates a widespread endothelial dysfunction. Zoneraich et al 
demonstrated small vessel disease in 72% of diabetic patients
61
. 
Microvascular changes include formation of microaneurysms and capillary 
membrane thickening.
62
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Deposition of advanced-glycated end products (AGEs), which include 
collagen, elastin and other connective tissue proteins in the interstitial spaces, 
as well as fibrosis in the myocardium have been reported in biopsy specimens 
of human diabetic hearts.65 
Thus with available data from our study and supporting data, the existence of 
diastolic dysfunction in diabetics, who are normotensive and free from 
coronary artery disease is confirmed. More importantly diastolic dysfunction 
exists in isolated form and is asymptomatic. The possible pathogenic 
mechanism for diastolic dysfunction has been proposed   due its strong 
association with microvascular complications.  
Newer modalities of diabetic treatment targeting the pathogenic mechanisms 
like aldose reductase inhibitors, PKC pathway inhibitors, ACE inhibitors can 
reverse diastolic dysfunction and improve cardiovascular mortality. 
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CONCLUSION 
As per our study performed on 60 patients with type 2 diabetes free of 
coronary artery disease and hypertension, 
• Diastolic dysfunction is common in individuals with type 2 diabetes. 
Grade I diastolic dysfunction is more commonly encountered. Grade 
III and Grade IV diastolic dysfunction were not encountered. Diastolic 
dysfunction in our study was isolated and asymptomatic.  
• Increasing age in diabetic patients is a risk factor for diastolic 
dysfunction. The risk is substantially increased above the age of 60. 
• Sex does not influence diastolic dysfunction in diabetes. Our study did 
not document a statistical significance. 
• Duration of type 2 diabetes positively correlates with diastolic 
dysfunction. Longer the duration of diabetes, greater is the prevalence 
of diastolic dysfunction. 
• Modality of treatment does not influence the outcome of diabetes with 
respect to diastolic dysfunction.  
• Triglyceride levels though statistically significant in our study, require 
further confirmation. Patients with triglyceride levels < 150 mg/dl did 
not develop diastolic dysfunction. 
• Obesity has a positive correlation with diastolic dysfunction. The 
association is strong when BMI values > 30 kg/m
2
. 
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• Microvascular complications like retinopathy and nephropathy 
strongly correlates with diastolic dysfunction. The association is 
greater for proliferative retinopathy and macroalbuminuria. 
• Cardiac disease in diabetes is no longer only a macrovascular disease, 
but microvascular changes do play a role.  
• Our study recommends screening of diabetic patients for diastolic 
dysfunction, especially those with duration of diabetes > 5 years, obese 
individuals, old age and patients with microvascular complications 
even if they are asymptomatic. 
A Doppler echocardiography is an easily available tool that can be used for 
screening purposes. 
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 ABBREVIATIONS 
ADA  American Diabetes Association  
AGE  Advanced Glycation End products 
AT II  Angiotensin II 
BMI  Body Mass Index 
CAN  Cardiac Autonomic Neuropathy 
CSME  Clinically Significant Macular Edema 
ESRD  End Stage Renal Disease 
FFA  Free fatty acids 
GDM  Gestational diabetes mellitus 
GFR  Glomerular filtration rate 
Hb A1C Glycosylated haemoglobin 
HDL  High Density Lipoprotein 
IFG  Impaired Fasting Glucose 
IGT  Impaired Glucose Tolerance 
LDL  Low density lipoprotein 
NPDR  Non proliferative diabetic retinopathy 
NVD  Neovascularisaction at disc 
NVE  Neovascularisation elsewhere 
PDR  Proliferative diabetic retinopathy 
PDGF  Platelet derived growth factor 
PKC  Protein Kinase C 
RAAS  Renin Angiotensin Aldosterone System 
VLDL  Very low density lipoprotein 
VEGF  Vascular endothelial growth factor 
  
 PROFORMA 
 
Name : Age :  Sex : 
Address : Occupation :   
SYMPTOMS 
Dyspnea     : Yes               No  
Orthopnea     : Yes               No  
PND      : Yes               No  
Chest pain     : Yes               No  
Oliguria     : Yes               No  
Abdominal distension   : Yes               No  
Swelling of legs    : Yes               No  
Puffiness of Face    : Yes               No  
Burning micturition    : Yes               No  
Numbness/Parasthesias   : Yes               No  
Blurring of vision    : Yes               No  
PAST HISTORY 
Diabetes Mellitus    : Yes               No  
• Duration    : 
• Treatment    : OHA / Insulin  
• Compliance of treatment  : 
• Other co-morbid illnesses 
PERSONAL HISTORY  
Smoking      : Yes               No  
Alcoholism     : Yes               No  
GENERAL EXAMINATION  
Authropometry 
Height (in m) :  Weight (in kg) :  BMI : 
Pulse 
Blood Pressure 
 
 SYSTEMIC EXAMINATION 
CVS :  RS :  ABDOMEN :  CNS : 
FUNDUS EXAMINATION  
INVESTIGATIONS 
Hemogram 
TC  : cells/mm
3
   DC  : 
ESR  : mm/hr    Hb  : g/dl 
PCV  : %    Platelets : lakhs/mm
3
 
RBCs  : million/mm
3
  
Renal Function Test 
Glucose (F) : mg/dl    Glucose (PP) : mg/dl   
Urea  : mg/dl    Creatinie : mg/dl 
Na
+
  : mEq/l    K+  : mEq/l 
Lipid Profile 
Total cholesterol   : mg/dl 
LDL     : mgs/dl 
HDL     : mg/dl 
Triglycerides    : mg/dl 
Urinanalysis 
Sugar 
Deposits 
Albumin 
Creatinine 
Albumin to Creatinine Ratio (ACR) 
Culture 
Ultra sonogram of Kidneys 
ECG 
ECHO CARDIOGRAM: 
 Left ventricular dimensions/ejection fraction 
 Diastolic dysfunction 
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1 Nagammal F 55 8 OHA R Nil N 27 NPDR 8.9 112 264 167 160 256.5 0.64 1.1 0.58182 I 
2 Mani M 62 12 OHA R N Y 27 NPDR 9.1 116 212 187 156 243 0.435 0.604 0.7202 I 
3 Kirubakaran M 35 0 
  
Y Y 24 Normal 10.4 185 351 213 7.7 16.8 1.07 0.53 2.01887 N 
4 Rajeswari F 45 7 I R N N 32 NPDR 10.5 242 207 150 22 13.6 0.54 0.764 0.70681 I 
5 Samuel M 38 0 
  
N N 25 Normal 14 234 180 500 160 98.6 0.61 0.54 1.12963 N 
6 James Paul M 45 5 I R N Y 23 Normal 7.8 312 360 340 2.5 18.6 0.864 0.54 1.6 N 
7 Lakshmipathy M 47 5 OHA R N N 24 Normal 11.2 123 186 164 2.2 16.4 0.613 0.41 1.49512 N 
8 Gnanam F 60 10 OHA/I R N N 26 PDR 10.9 298 181 176 160 256.5 0.64 1.1 0.58182 I 
9 Maniammal F 32 0 
  
N N 28 Normal 7.8 246 212 135 4.4 24.7 0.763 0.546 1.39744 N 
10 Saroja F 50 10 OHA R N N 26 Normal 10.7 106 160 265 2.5 25 0.604 0.41 1.47317 N 
11 Vasanthin F 50 12 OHA R N N 28 NPDR 9.2 65 147 235 160 467.7 0.81 1.1 0.73636 I 
 12 Ellammal F 58 15 OHA R N N 31 NPDR 12.4 163 220 147 54 133.2 0.78 0.542 1.43911 N 
13 Beenabevi F 59 20 OHA R N N 26 NPDR 7.1 102 232 246 46 148.3 0.81 1.07 0.75701 I 
14 Vadivel M 58 1 OHA I Y Y 28 Normal 10.1 160 246 160 2.5 6.7 0.604 0.435 1.38851 N 
15 Bharathi F 31 0 
  
N N 24 Normal 7.5 206 211 157 22 114.1 1.07 0.53 2.01887 N 
16 Arumugam M 58 10 OHA R Y Y 32 NPDR 9.4 185 234 207 81.4 109.9 1.46 0.88 1.65909 II 
17 Irudhayaraj M 42 5 OHA R N Y 25 Normal 9.8 247 217 118 3.3 19.3 0.9 0.73 1.23288 N 
18 Job M 57 10 OHA R N N 26 NPDR 13.7 160 143 340 2.5 17.7 0.94 1.02 0.92157 I 
19 Paneerselvam M 53 5 OHA R Y Y 24 NPDR 11.2 169 164 169 16.1 45.6 0.954 0.84 1.13571 N 
20 Sriramulu M 62 2 OHA I N Y 21 NPDR 7.8 144 195 115 18.1 33.5 1.07 0.93 1.15054 N 
21 Sundari F 56 6 OHA/I R N N 31 NPDR 10.4 151 195 280 2.5 16.8 0.735 0.61 1.20492 N 
22 Arul doss M 60 7 OHA R Y N 30 NPDR 4.4 134 205 279 92.3 522.7 0.98 0.5 1.96 II 
23 Mathammal F 52 7 I R N N 26 NPDR 11.9 214 176 220 7.9 68.6 0.611 0.742 0.82345 I 
24 Shanthi F 38 15 I R N N 27 PDR 9.1 183 201 322 160 344.6 0.845 1.02 0.82843 I 
25 Muthuraman M 42 0 
  
N N 26 Normal 8.6 232 213 312 160 291.2 Jan-00 1.02 1.18627 N 
26 Solomon M 33 0 
  
Y Y 23 Normal 10.3 210 191 206 2.2 21.6 0.76 0.62 1.22581 N 
27 Krishnaiah M 46 5 OHA R Y Y 31 NPDR 9.6 110 210 200 17.4 56.1 0.763 0.543 1.40516 N 
28 Dhanalakshmi F 56 11 I R N N 25 NPDR 11.6 142 246 178 78.2 106.3 0.845 1.14 0.74123 I 
 29 Chakravarthi M 64 13 I R Y Y 28 PDR 7.8 110 213 256 91.4 526.4 0.78 0.984 0.79268 I 
30 Raja M 66 6 OHA R Y Y 30 NPDR 12.4 86 165 196 19.4 56.77 0.912 1.04 0.87692 I 
31 Pushpavalli F 36 1 OHA R N N 29 Normal 11.5 95 190 145 3.2 23.4 1.03 0.87 1.18391 N 
32 lalitha F 55 2 OHA R N N 25 Normal 12.1 102 184 220 2.6 16.4 0.98 0.76 1.28947 N 
33 Ranjitham F 38 5 OHA R N N 28 Normal 10.6 206 194 196 8.4 59.5 0.703 0.912 0.77083 I 
34 Kanikaanan M 43 7 OHA/I R Y Y 26 NPDR 9.7 213 186 156 49 151.2 0.56 0.864 0.64815 I 
35 Selvaraj M 47 1 OHA R Y N 26 Normal 10.7 145 240 165 8.4 26.2 1.12 0.92 1.21739 N 
36 Manickam M 67 16 OHA/I I Y Y 28 NPDR 12.2 186 165 256 19.3 48.2 0.98 1.1 0.89091 I 
37 Jothi F 42 4 OHA R N N 26 Normal 12.3 145 142 220 34.1 121 0.67 0.832 0.80529 I 
38 Mallika F 36 1 OHA I N N 27 Normal 14.2 125 163 175 6.5 25.4 0.765 0.645 1.18605 N 
39 Vnayagam M 46 3 OHA R Y Y 32 Normal 10.1 154 207 310 54.2 151.2 0.95 1.13 0.84071 I 
40 Kanakkammal F 62 9 I R N N 26 NPDR 13.1 98 190 186 46.1 143.3 0.546 0.765 0.71373 I 
41 Madhaiyyan M 61 10 OHA R Y Y 34 NPDR 7.9 133 174 165 68.7 213.5 0.653 0.812 0.80419 I 
42 Kala F 48 4 OHA R N N 24 Normal 8.7 210 208 354 54.2 151.2 0.985 0.862 1.14269 N 
43 Kumerasan F 43 9 I R N N 25 PDR 12.1 190 218 165 160 421.8 0.64 0.85 0.75294 I 
44 Vendammal F 39 0 
  
N N 24 Normal 10.4 176 173 145 2.2 12.1 0.675 0.563 1.19893 N 
45 Subramanian M 36 1 OHA I Y Y 24 Normal 13.3 120 194 205 18.6 36 0.765 1.12 0.68304 I 
 46 Murugan M 63 13 OHA R N Y 24 NPDR 12.2 230 157 185 154 321.1 0.859 1.14 0.75351 I 
47 Naseer M 43 2 OHA I Y Y 21 Normal 11.1 187 200 247 19.3 43.4 0.654 0.985 0.66396 I 
48 Govindasamy M 64 13 OHA/I R N Y 28 PDR 8.1 134 185 184 20.7 67 0.876 0.953 0.9192 I 
49 Isaac M 34 1 OHA R Y Y 24 Normal 10.4 125 173 173 2.5 12.4 0.78 0.64 1.21875 N 
50 Vembuli M 55 5 OHA I Y Y 26 NPDR 12.3 136 197 165 153 265.3 0.715 0.965 0.74093 I 
51 Mohammad Mooran M 43 6 I R N N 27 NPDR 12.8 174 208 195 54.6 212.3 0.87 1.2 0.725 I 
52 Napinnai F 56 4 OHA R N N 25 Normal 10.8 138 254 202 34.3 135.2 0.65 0.931 0.69817 I 
53 Sundaravadivu F 65 7 OHA I N N 25 NPDR 11.3 198 167 156 44.5 200.6 1.03 1.12 0.91964 I 
54 Aleem basha M 34 0 
  
Y Y 29 Normal 12.6 102 183 182 2.2 8.6 0.7 0.54 1.2963 N 
55 Rajendran M 52 6 I R N Y 30 Normal 11 96 221 173 36.5 126.4 0.87 0.972 0.89506 I 
56 Thangamani F 58 10 I R N N 25 NPDR 11.6 94 228 165 31.1 132 0.53 0.821 0.64555 I 
57 Sekar M 34 1 OHA R Y Y 26 Normal 12.2 126 146 214 4.2 24.2 0.602 0.54 1.11481 N 
58 Ezhil M 39 0 
  
N Y 24 Normal 11.8 198 165 312 2.5 16.4 0.813 0.653 1.24502 N 
59 Ramasamy M 60 6 OHA R N Y 24 Normal 10.9 184 178 156 36.3 167 1.07 1.23 0.86992 I 
60 Murugalakshmi F 51 10 OHA/I I N N 29 NPDR 10.8 242 154 214 34.2 146 0.78 0.934 0.83512 I 
  
 
 
  
 
